Oppenheimer set a $10.00 price objective on Mediwound (NASDAQ:MDWD) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

MDWD has been the topic of a number of other research reports. Jefferies Group set a $10.00 target price on Mediwound and gave the company a buy rating in a research report on Friday, August 25th. SunTrust Banks set a $9.00 target price on Mediwound and gave the company a buy rating in a research report on Thursday, November 16th. Zacks Investment Research lowered Mediwound from a buy rating to a hold rating in a research report on Tuesday, November 21st. ValuEngine raised Mediwound from a strong sell rating to a sell rating in a research report on Saturday, November 25th. Finally, Cowen started coverage on Mediwound in a research report on Thursday, September 28th. They issued an outperform rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $9.13.

Shares of Mediwound (NASDAQ:MDWD) opened at $4.70 on Friday. Mediwound has a 1 year low of $4.15 and a 1 year high of $8.25.

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its position in shares of Mediwound by 1.7% during the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 1,300 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Mediwound by 23.5% during the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after purchasing an additional 12,522 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Mediwound by 9.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock worth $11,882,000 after purchasing an additional 192,860 shares during the last quarter. Nationwide Fund Advisors acquired a new position in shares of Mediwound during the 3rd quarter worth approximately $1,538,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Mediwound during the 3rd quarter worth approximately $2,140,000. 29.46% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/12/mediwound-mdwd-given-a-10-00-price-target-at-oppenheimer.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for Mediwound (NASDAQ:MDWD)

Receive News & Stock Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related stocks with our FREE daily email newsletter.